ProCE Banner Activity

Once-Weekly Oral ISL Plus LEN for HIV Treatment: Australian Perspective

Conference Coverage
Clinical Thought

Read an expert’s perspective on how the results of a phase II trial of once-weekly oral islatravir plus lenacapavir, presented at CROI 2024, may offer another option beyond a single-tablet daily regimen for HIV care in Australia.

Released: April 03, 2024

Expiration: April 02, 2025

Share

Faculty

Andrew Carr

Andrew Carr, DSc, MD, MBBS, FRACP, FRCPA

Senior Staff Specialist in Clinical Immunology and Immunopathology
St. Vincent’s Hospital, Sydney
Professor of Medicine
University of New South Wales Sydney
Sydney, Australia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Disclosure

Primary Author

Andrew Carr, DSc, MD, MBBS, FRACP, FRCPA

Senior Staff Specialist in Clinical Immunology and Immunopathology
St. Vincent’s Hospital, Sydney
Professor of Medicine
University of New South Wales Sydney
Sydney, Australia

Andrew Carr, DSc, MD, MBBS, FRACP, FRCPA: consultant/advisor/speaker: Gilead, Merck Sharpe & Dohme, ViiV Healthcare.